CNS Pharmaceuticals Inc
CNSP
Company Profile
Business description
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Contact
2100 West Loop South
Suite 900
HoustonTX77027
USAT: +1 800 946-9185
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,465.00 | 44.50 | 0.53% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,417.35 | 126.87 | -0.30% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,623.32 | 436.63 | -2.18% |
| NASDAQ | 19,264.97 | 45.83 | -0.24% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,867.45 | 14.18 | -0.24% |
| S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
| SSE Composite Index | 3,262.56 | 89.20 | -2.66% |